Botulinum toxin type B

Botulinum toxin type B is a medically relevant serotype with a smaller product footprint than type A. Its current U.S. role is easiest to understand through Myobloc / Neurobloc, where Myobloc functions as a focused therapeutic type B reference rather than as a broad aesthetic peer to the major type A brands.

Product And Label Context

Myobloc is the U.S. brand name for rimabotulinumtoxinB; Neurobloc is the related name used in some non-U.S. contexts. Supernus Pharmaceuticals is the current U.S. commercial company node. In current U.S. prescribing information, Myobloc is labeled for cervical dystonia and chronic sialorrhea in adults.

The focused footprint should not be mistaken for irrelevance. Type B defines an important boundary between serotype biology, product labeling, unit systems, treatment history, and practical treatment selection.

Mechanism Context

Type B reaches the same broad endpoint as other botulinum toxins: reduced release of selected nerve signals. The important biologic distinction is its intracellular target. Type B acts on synaptobrevin, also called VAMP, which is part of the SNARE machinery involved in signal release from nerve endings.

Botulinum toxin type A acts on a different SNARE protein, SNAP-25. That difference does not create a simple ranking, but it does matter when readers interpret serotype comparison, immunogenicity discussion, and product-specific clinical evidence.

Therapeutic Role

Type B is most visible in selected therapeutic settings rather than broad aesthetic practice. Myobloc’s U.S. label includes cervical dystonia and chronic sialorrhea in adults, while broader type B discussion may also involve prior response to type A treatment, tolerability, patient history, and local availability.

Those discussions still remain product-specific. A type B unit is not a type A unit under another name, and type B’s different serotype does not by itself answer questions about duration, tolerability, spread, or suitability for a particular patient.

Comparison With Type A

Type A is more visible because it has more product nodes, broader aesthetic presence, and wider indication coverage in the current market and literature. Type B is more specialized. The comparison is therefore about mechanism, label context, unit interpretation, treatment history, tolerability, and indication fit rather than about which serotype is generally better.

For the side-by-side reading framework, see botulinum toxin type A vs type B. For response durability and antibody discussion, see botulinum toxin immunogenicity.